Drugs / LY3316531
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03611608 | Aug 2018 → Mar 2019 | — | Eli Lilly and Company | Completed | Met primary |
| Phase 1 | NCT03418493 | Jan → Dec 2018 | psoriasis | Eli Lilly and Company | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY3316531 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03611608 ↗ |
| Route | Intravenous | “Administered IV.” NCT03418493 ↗ |